EUVIMEDEUVIMED entdecken
Vergleichsstudie

Time-dependent divergence in infection risks among patients with multiple sclerosis treated with fumarates versus anti-CD20 monoclonal antibodies

Kyle Smoot iD, Erin E Longbrake iD, Mirla Avila, Sarah F Wesley iD, Afif Hentati, William Meador, John Scagnelli, Lynsey L Lakin, Mark Gudesblatt iD, Boyang Bian iD, Jason P Mendoza iD, Nicholas Belviso iD und 3 weitere

Multiple Sclerosis Journal · 2026

DOI: 10.1177/13524585261475232 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Multiple Sclerosis Journal, 2026. Verfasst von Kyle Smoot und 14 weiteren Autor:innen. Beteiligte Einrichtung: Providence Neurological Specialties, Portland, OR, USA. Hauptthemen laut MEDLINE: Multiple Sclerosis, Antigens, CD20, Fumarates, Rituximab. Die Arbeit nennt 35 Literaturangaben. Gefördert von: Biogen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

People with multiple sclerosis (pwMS) treated with anti-CD20 monoclonal antibodies have an elevated infection risk, yet long-term comparative data with oral fumarates are limited.

Objective

To compare infection incidence, healthcare resource utilization, and relapse outcomes among pwMS receiving fumarate or anti-CD20 therapy for ⩾2 years.

Methods

This retrospective propensity-matched (1:2) analysis used US Komodo Health claims (1 January 2016–31 May 2022) for pwMS aged 18–64 years with ⩾2 years of continuous follow-up. Outcomes were assessed using Poisson generalized linear models.

Results

A total of 1956 pwMS were matched (fumarates: n = 652; anti-CD20s: n = 1304), with mean follow-up ~3 years. By year 2, the fumarates group had a lower infection rate than anti-CD20s (rate ratio: 0.84; 95% CI: 0.73–0.97; p = 0.016), but the most substantial difference was observed in years 4+, where fumarate-treated patients had a 30% reduction versus anti-CD20s (rate ratio: 0.70; 95% CI: 0.52–0.95; p = 0.021).

Conclusions

Fumarate therapy was associated with a lower infection risk versus anti-CD20s. The infection rate in the fumarates group remained relatively stable over time, but it progressively increased in the anti-CD20 group, with the most prominent differences observed at year 4 and beyond.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple SclerosisAntigens, CD20FumaratesRituximabAntibodies, MonoclonalInfectionsImmunosuppressive AgentsHumansAdultMiddle AgedFemaleRetrospective StudiesMaleYoung AdultAdolescentIncidenceTime Factors

Stichwörter der Autor:innen

Multiple sclerosisanti-CD20 monoclonal antibodydisease-modifying therapyfumaratesinfectionreal-world evidence

Substanzen

Antigens, CD20FumaratesRituximabAntibodies, MonoclonalImmunosuppressive Agents

Autor:innen und Institutionen

  • Providence Neurological Specialties, Portland, OR, USA.
  • Yale University, New Haven, CT, USA.
  • Texas Tech University Health Sciences Center, Lubbock, TX, USA.
  • Columbia University, New York, NY, USA.
  • Northshore Endeavor Health, Evanston, IL, USA.
  • University of Alabama at Birmingham, Birmingham, AL, USA.

ORCID-Profile: Kyle Smoot, Erin E Longbrake, Sarah F Wesley, Mark Gudesblatt, Boyang Bian, Jason P Mendoza, Nicholas Belviso, James B Lewin, Sai L Shankar, Ahmed Z Obeidat

Förderung

  • Biogen

Zitieren

APA

Smoot, K., Longbrake, E. E., Avila, M., Wesley, S. F., Hentati, A., Meador, W., Scagnelli, J., Lakin, L. L., Gudesblatt, M., Bian, B., Mendoza, J. P., Belviso, N., Lewin, J. B., Shankar, S. L., & Obeidat, A. Z. (2026). Time-dependent divergence in infection risks among patients with multiple sclerosis treated with fumarates versus anti-CD20 monoclonal antibodies. Multiple Sclerosis Journal. https://doi.org/10.1177/13524585261475232

Vancouver

Smoot K, Longbrake EE, Avila M, Wesley SF, Hentati A, Meador W, et al. Time-dependent divergence in infection risks among patients with multiple sclerosis treated with fumarates versus anti-CD20 monoclonal antibodies. Multiple Sclerosis Journal. 2026. doi:10.1177/13524585261475232

BibTeX
@article{Smoot2026,
  author = {Smoot, Kyle and Longbrake, Erin E and Avila, Mirla and Wesley, Sarah F and Hentati, Afif and Meador, William and Scagnelli, John and Lakin, Lynsey L and Gudesblatt, Mark and Bian, Boyang and Mendoza, Jason P and Belviso, Nicholas and Lewin, James B and Shankar, Sai L and Obeidat, Ahmed Z},
  title = {Time-dependent divergence in infection risks among patients with multiple sclerosis treated with fumarates versus anti-CD20 monoclonal antibodies},
  journal = {Multiple Sclerosis Journal},
  year = {2026},
  doi = {10.1177/13524585261475232}
}
Kostenlos starten →